Eltanexor — Investigational Agent
Other · Phase 1/2 · Karyopharm Therapeutics
Mechanism of Action
Second-generation oral selective inhibitor of nuclear export (SINE) that covalently binds XPO1/CRM1, forcing nuclear retention and reactivation of tumor-suppressor proteins; lower CNS penetration than selinexor for improved tolerability.
Investigational Indications
- Myelodysplastic syndromes
- Acute myeloid leukemia